MyoPax GmbH
MyoPax is a female-founded biotechnology company with operations in Germany and Denmark. It uses a proprietary, patented, first-in-class stem cell technology to become the leading engineering platform for the treatment of skeletal muscle wasting disorders, aiming to restore muscle function through effective regenerative therapies.
Problem
Muscle wasting and weakness are leading symptoms of a wide variety of diseases. Dysfunction can affect all muscles or only a single muscle, which impairs quality and can shorten lifespan. Muscle diseases are currently untreatable. In Europe alone, more than 20 million people are affected by the devastating consequences of muscle wasting. Only palliative care is available.
Solution
MyoPax has developed a patented autologous muscle stem cell therapy to treat muscle wasting. The team’s technological innovation enables highly standardized manufacturing of pure, native and highly regenerative muscle stem cells from small human muscle tissue samples to treat acquired and inherited muscle diseases.
